• 1
    Robins LN, Hezler JE, Orvaschel C et al. The diagnostic interview schedule. In : EatonWW, KesslerLG (eds). Epidemiologic Field Methods in Psychiatry: The NIMH Epidemiologic Catchment Area Program. Academic Press, Orlando, FL, 1985; 143168.
  • 2
    Graybiel AM, Rauch SL. Toward a neurobiology of obsessive-compulsive disorder. Neuron 2000; 28: 343347.
  • 3
    Scarone S, Colombo C, Livian S et al. Increased right caudate nucleus size in obsessive-compulsive disorder: Detection with magnetic resonance imaging. Psychiatry Res. 1992; 45: 115121.
  • 4
    Robinson D, Wu H, Munne RA et al. Reduced caudate nucleus volume in obsessive-compulsive disorder. Arch. Gen. Psychiatry 1995; 52: 393398.
  • 5
    Szeszko PR, Robinson D, Alvir JM et al. Orbital frontal and amygdala volume reductions in obsessive-compulsive disorder. Arch. Gen. Psychiatry 1999; 56: 913919.
  • 6
    Jenike MA, Breiter HC, Baer L et al. Cerebral structural abnormalities in obsessive-compulsive disorder. A quantitative morphometric magnetic resonance imaging study. Arch. Gen. Psychiatry 1996; 53: 625632.
  • 7
    Riffkin M, Yucel M, Maruff P et al. A manual and automated MRI study of anterior cingulate and orbito-frontal cortices, and caudate nucleus in obsessive-compulsive disorder: Comparison with healthy controls and patients with schizophrenia. Psychiatry Res. 2005; 138: 99113.
  • 8
    Rosenberg DR, Benazon NR, Gilbert A, Sullivan A, Moore GJ. Thalamic volume in pediatric obsessive–compulsive disorder patients before and after cognitive behavioral therapy. Biol. Psychiatry 2000; 48: 294300.
  • 9
    Kang DH, Kim JJ, Choi JS et al. Volumetric investigation of the frontal-subcortical circuitry in patients with obsessive-compulsive disorder. J. Neuropsychiatry Clin. Neurosci. 2004; 16: 342349.
  • 10
    Altemus M, Pigott T, Kalogeras KT et al. Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder. Arch. Gen. Psychiatry 1992; 49: 920.
  • 11
    Catapano F, Monteleone P, Fuschino A, Maj M, Kemali D. Melatonin and cortisol secretion in patients with primary obsessive-compulsive disorder. Psychiatry Res. 1992; 44: 217225.
  • 12
    Monteleone P, Catapano F, Tortorella A, Maj M. Cortisol response to d-fenfluramine in patients with obsessive-compulsive disorder and in healthy subjects: Evidence for a gender-related effect. Neuropsychobiology 1997; 36: 812.
  • 13
    Kluge M, Schüssler P, Künzel HE, Dresler M, Yassouridis A, Steiger A. Increased nocturnal secretion of ACTH and cortisol in obsessive compulsive disorder. J. Psychiatr. Res. 2007; 41: 928933.
  • 14
    MacMaster FP, Russell A, Mirza Y et al. Volume in pediatric obsessive-compulsive disorder. Biol. Psychiatry 2006; 59: 252257.
  • 15
    Çorapçıoglu A, Aydemir O, Yıldız M et al. DSM-IV Eksen I Bozuklukları (SCID-I) İçin Yapılandırılmış Klinik Görüşme, Klinik Versiyon. Hekimler Yayın Birligi, Ankara, 1999.
  • 16
    Goodman WK, Price LH, Rasmussen SA et al. The Yale–Brown Obsessive Compulsive Scale II. Validity. Arch. Gen. Psychiatry 1989; 46: 10121016.
  • 17
    Daniels DL, Haughton VM, Naidich TP. Cranial and Spinal Magnetic Resonance İmaging an Atlas and Guide. Raven Press, New York, 1987.
  • 18
    Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain. Thieme-Stratton, New York, 1988.
  • 19
    Krishnan KR, Doraiswamy PM, Lurie SN et al. Pituitary size in depression. J. Clin. Endocrinol. Metab. 1991; 72: 256259.
  • 20
    MacMaster FP, Kusumakar V. MRI study of the pituitary gland in adolescent depression. J. Psychiatr. Res. 2004; 38: 231236.
  • 21
    Sassi RB, Nicoletti M, Brambilla P et al. Decreased pituitary volume in patients with bipolar disorder. Biol. Psychiatry 2001; 50: 271280.
  • 22
    Thomas LA, De Bellis MD. Pituitary volumes in pediatric maltreatment-related posttraumatic stress disorder. Biol. Psychiatry 2004; 55: 752758.
  • 23
    Chappelli P, Leckman J, Goodman W et al. Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: Comparison to obsessive compulsive disorder and normal controls. Biol. Psychiatry 1996; 39: 776783.
  • 24
    Cottraux JA, Bouvard M, Claustrat B, Juenet C. Abnormal dexamethasone suppression test in primary obsessive-compulsive patients: A confirmatory report. Psychiatry Res. 1984; 13: 157165.
  • 25
    Coryell WH, Black DW, Kelly MW, Noyes R Jr. HPA axis disturbance in obsessive-compulsive disorder. Psychiatry Res. 1989; 30: 243251.
  • 26
    Jenike MA, Baer L, Brotman AW, Goff DC, Minichiello WE, Regan NJ. Obsessive-compulsive disorder, depression, and the dexamethasone suppression test. J. Clin. Psychopharmacol. 1987; 7: 182184.
  • 27
    Lieberman JA, Kane JM, Sarantakos S et al. Dexamethasone suppression tests in patients with obsessive-compulsive disorder. Am. J. Psychiatry 1985; 142: 747751.
  • 28
    Meltzer HY. Clinical studies on the mechanism of action of clozapine: The dopamine–serotonin hypothesis of schizophrenia. Psychopharmacology 1989; 99: 1827.
  • 29
    Wik G. Effects of neuroleptic treatment on cortisol and 3-methoxy-4-hydroxyphenylethyl glycol levels in blood. J. Endocrinol. 1995; 144: 425429.
  • 30
    Chakeres DW, Curtin A, Ford G. Magnetic resonance imaging of pituitary and parasellar abnormalities. Radiol. Clin. North Am. 1989; 27: 265281.
  • 31
    Gonzalez JG, Elizondo G, Saldivar D, Nanez H, Todd LE, Villarreal JZ. Pituitary gland growth during normal pregnancy: An in vivo study using magnetic resonance imaging. Am. J. Med. 1988; 85: 217220.